Summary
Pfizer Inc. (PFE) filed an 8-K on July 16, 2001, to report accounting adjustments and provide restated consolidated statements of operations for specific quarters and the full year of 2000. The primary focus of this filing is the adoption of Emerging Issues Task Force (EITF) Issue No. 00-14, which impacts the income statement classification of certain sales incentives. Additionally, the company harmonized accounting methodologies between Pfizer and the former Warner-Lambert Company, leading to reclassifications of royalty expenses and other sales incentives. These adjustments primarily involved reclassifying costs between "Selling, informational and administrative expenses" and "Revenues," as well as royalty expenses between "Other income-net" and "Cost of sales." Importantly, the company states that these reclassifications have no impact on net income. The filing also includes unaudited restated financial statements for the quarters ended April 2, July 2, October 1, 2000, and the quarter and year ended December 31, 2000, which incorporate the results of the Warner-Lambert merger accounted for as a pooling of interests.
Key Highlights
- 1Adoption of EITF Issue No. 00-14 related to accounting for certain sales incentives, effective January 1, 2001.
- 2Accounting adjustments made to harmonize accounting methodologies between Pfizer and the former Warner-Lambert Company.
- 3Reclassification of certain sales incentives between Selling, informational and administrative expenses and Revenues.
- 4Reclassification of royalty expenses between Other income-net and Cost of sales.
- 5Crucially, these reclassifications did not affect the company's reported net income.
- 6Filing includes unaudited restated consolidated statements of operations for specific quarters and the full year of 2000.
- 7Restated financial data incorporates the Warner-Lambert merger, accounted for as a pooling of interests.